Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agenus Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

70 comunicati stampa

Guarda tutti i comunicati
02/06/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Eventi
Finanza
Agenus Announces Virtual 2026 Annual Shareholders Meeting
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Eventi
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Eventi
Industria
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Medicina - Varie
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
15/05/2026
Industria
Sanità
Farmaceutica
Oncologia
Vetrine/Shopping
Biotecnologia
Medicina - Varie
Assistenza all'Infanzia
Terza età
Igiene alimentare
Salute
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Mercato azionario
Mercato del lavoro
Web e Social Network
Oncologia
Associazioni/Professionisti
Salute
Legge/Diritto
Medicina - Varie
Farmaceutica
Biotecnologia
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Web e Social Network
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Industria
Biotecnologia
Salute
Oncologia
Medicina - Varie
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
26/03/2026
Web e Social Network
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0
16/03/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
Fonte
Agenus Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0